Evidence map›Paper›PMID 14981009›Full record

Trial reportCirculation2004

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.

Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon

7 registry-linked trialsAbstract readClinical TrialControlled Clinical Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 322 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
322citing papers in PubMed, 6 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01761318 phase4completedstarted 2013, after this paper: background citation

Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus

Ran2013Enrolled50Registered outcomes48Posted comparisons0ConditionsCardiovascular Disease, Diabetes Mellitus Type 2, Diastolic Dysfunction, Fatty LiverArmsliraglutide, Liraglutide - Placebo
PMID 16776751PMID 18819705PMID 19915017PMID 19349323PMID 19930006PMID 15591516PMID 11707564PMID 11897280PMID 11997279PMID 12840659PMID 12875772PMID 15111519other papers from this trial
Open the trial in the graph
NCT02490176 naunknown statusstarted 2015, after this paper: background citation

Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure

Ran2015Enrolled50Registered outcomes2Posted comparisons0ConditionsHeart FailureArmsliraglutide, Placebo
PMID 19151200PMID 18688814PMID 18724013PMID 19195607PMID 21263372PMID 21920963other papers from this trial
Open the trial in the graph
NCT04575844 phase4recruitingstarted 2020, after this paper: background citation

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Ran2020Enrolled80Registered outcomes6Posted comparisons0ConditionsMetabolic SyndromeArmsExercise Training, liraglutide, Liraglutide + Exercise training
PMID 28237263PMID 27295427PMID 23899560PMID 10600857PMID 10843167PMID 11078458PMID 11916935PMID 12107720PMID 12791603PMID 14966043PMID 15084712PMID 15161743other papers from this trial
Open the trial in the graph
NCT00256256 nacompletednot on this mapstarted 2005, after this paper: background citation

The Effect of GLP-1 on Glucose Uptake in the CNS and Heart in Healthy Subjects During Normoglycaemia Assessed by Positron Emission Tomografi

TypeinterventionalSponsorUniversity of AarhusRan2005 to 2007Enrolled10ConditionsType 2 Diabetes, Stroke, Myocardial InfarctionArmsglucagon-like-peptide-1
NCT00923962 nacompletednot on this mapstarted 2009, after this paper: background citation

Endothelial and Metabolic Effects of GLP-1 in Coronary Circulation in Patients With Type 2 Diabetes Mellitus

TypeinterventionalSponsorUniversity Hospital, Gentofte, CopenhagenRan2009 to 2012Enrolled35ConditionsType 2 Diabetes MellitusArmsGlucagon like peptide-1, Adenosine
NCT02602600 phase4completednot on this mapstarted 2015, after this paper: background citation

Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels

TypeinterventionalSponsorEva PrescottRan2015 to 2017Enrolled33ConditionsMicrovascular AnginaArmsLiraglutide
NCT02694575 completednot on this mapstarted 2015, after this paper: background citation

The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes

TypeobservationalSponsorUniversity of LeicesterRan2015 to 2018Enrolled241ConditionsDiabetes Mellitus, Type 2, Cardiovascular Diseases
3 · Its place in the literature

Who cites it

322 citing papers in PubMed, 6 syntheses or guidelines pooled it, 896 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Admission glucose and risk of early death in non-diabetic patients with ST-segment elevation myocardial infarction: a meta-analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

262 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lazaros A NikolaidisCardiovascular Research Institute, Allegheny General Hospital, Pittsburgh, Pa 15212, USA.
Sunil Mankad
George G Sokos
Glen Miske
Ankur Shah
Dariush Elahi
Richard P Shannon
Allegheny General Hospital · US

Funding

Aging, Insulin Resistance, and Dilated CardiomyopathyR01AG023125 · UNIVERSITY OF PENNSYLVANIA · 2004 to 2005
$666k
NIA NIH HHS 1 R01 AG023125
6 · The paper itself

Abstract

backgroundGlucose-insulin-potassium infusions are beneficial in uncomplicated patients with acute myocardial infarction (AMI) but are of unproven efficacy in AMI with left ventricular (LV) dysfunction because of volume requirements associated with glucose infusion. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and insulinomimetic properties that stimulate glucose uptake without the requirements for concomitant glucose infusion. METHODS AND

resultsWe investigated the safety and efficacy of a 72-hour infusion of GLP-1 (1.5 pmol/kg per minute) added to background therapy in 10 patients with AMI and LV ejection fraction (EF) <40% after successful primary angioplasty compared with 11 control patients. Echocardiograms were obtained after reperfusion and after the completion of the GLP-1 infusion. Baseline demographics and background therapy were similar, and both groups had severe LV dysfunction at baseline (LVEF=29+/-2%). GLP-1 significantly improved LVEF (from 29+/-2% to 39+/-2%, P<0.01), global wall motion score indexes (1.94+/-0.11-->1.63+/-0.09, P<0.01), and regional wall motion score indexes (2.53+/-0.08-->2.02+/-0.11, P<0.01) compared with control subjects. The benefits of GLP-1 were independent of AMI location or history of diabetes. GLP-1 was well tolerated, with only transient gastrointestinal effects.

conclusionsWhen added to standard therapy, GLP-1 infusion improved regional and global LV function in patients with AMI and severe systolic dysfunction after successful primary angioplasty.

Indexed as

AdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBlood GlucoseCombined Modality TherapyDiabetes ComplicationsFemaleGlucagonGlucagon-Like Peptide 1Glucagon-Like PeptidesHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsBlood GlucoseGlucagonGlucagon-Like Peptide 1glucagon-like peptide 1 (7-36)amideGlucagon-Like PeptidesPeptide Fragments

Identifiers

PMID14981009
OpenAlexW1968315455

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.